In a retrospective cohort of 4,269 adults in a telemedicine obesity program, those receiving individualized carbohydrate-reduced nutritional therapy alongside incretin-based medications lost more weight at 12 months than those on medication with coaching alone. Among GLP-1-naive tirzepatide users, observed loss was 19.7% versus 15.6% (adjusted 45.9 vs 34.4 lb); for semaglutide, 13.3% versus 11.1%. Overall adjusted loss was 29.4 versus 21.5 lb, with similar medication adherence in both groups.
The gap is clinically meaningful, roughly 2 to 4 percentage points of body weight, and it fits the broader logic that drugs work better when paired with dietary structure, particularly given concerns about muscle loss and diminishing intake quality on GLP-1 therapy. But the design limits what can be concluded. This is a retrospective cohort, not a randomized trial, so patients who chose or were steered toward the nutrition pathway may differ in motivation, income, or engagement in ways mixed-effects adjustment cannot fully capture. The authors are affiliated with the program's operator, a commercial conflict worth weighing. Weight was the only reported outcome, so nothing is known about lean mass, cardiometabolic markers, or whether the low-carb approach beats other structured diets. This is a preprint and has not been peer reviewed, so the findings may change. The result is incremental and hypothesis-generating, supporting a randomized comparison rather than a change in practice.